Demographic information on cocaine exposed individuals contributing the time to cocaine use disorder analysis
| Cohort | AA | EA | ||||||
|---|---|---|---|---|---|---|---|---|
| Age μ (SD) | Sex N (%) male | CD cases (N, mean years to dependence) | CD controls (N, mean years to censoring) | Age μ (SD) | Sex N (%)male | CD (N, mean years to dependence) | CD controls (N, mean years to censoring) | |
| Yale-Penn | 42.5 (8.3) | 2,419 (60) | 3,554 (5.5) | 478 (17.8) | 38.0 (11.1) | 2,237 (62) | 2,712 (4.9) | 915 (16.3) |
| COGA | 56.9 (10.1) | 568 (57) | 572 (4.6) | 416 (13.8) | 52.1 (13.1) | 1380 (58) | 759 (3.9) | 1,620 (13.3) |
The supplementary materials for this article are available at:
JG, LAF, HRK, HJE, EN, NGM, and LD contributed conception and design of the study; CZ, EJ, and LW, and RS performed the statistical analysis; RS wrote the first draft of the manuscript; all authors contributed to manuscript revision, read and approved the submitted version.
Dr. Kranzler is a member of an advisory board for Dicerna Pharmaceuticals and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative (ACTIVE Group), which over the past three years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists”, filed January 24, 2018. In the past three years, Dr. Degenhardt has received untied educational grant funding from Indivior and Seqirus. No other authors reported potential conflicts of interest.
This study was approved by the Institutional Review Boards of Boston University, Yale University and the University of Pennsylvania.
Informed consent to participate in the study was obtained from all participants.
Not applicable.
Summary statistics for GWAS analyses will be provided by the corresponding author upon request.
This study was supported by National Institutes of Health grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, 2P50-AA012870, VA Connecticut Healthcare Center, Philadelphia VA MIRECCS, and National Center for Post Traumatic Stress Disorder. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2021.